The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the ...

Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in ...

Shares of Candel Therapeutics surged more than 100% on Wednesday, reaching seven-month highs, as the clinical-stage ...

Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a "Buy" ...

Candel Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing biological immunotherapies aimed at helping patients fight cancer. The company’s leading product, ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

Ryne Sandberg, the legendary Chicago Cubs second baseman and Baseball Hall of Famer, on Tuesday revealed that his metastatic ...

Shares of Candel Therapeutics took flight in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a late-stage study of its CAN-2409 product candidate met its key goal ...

Candel Therapeutics (CADL) announced results from a multicenter phase 3 clinical trial evaluating CAN-2409 viral immunotherapy in localized ...

It’s claimed cancer patients in Clare are routinely subjected to undignified and inhumane conditions due to a lack of local ...

Baseball Hall of Famer and Chicago Cubs icon Ryne Sandberg announced on Dec. 10 that his prostate cancer has relapsed and ...